Home Prostate / Prostate Cancer Clinical Utility of Molecular Markers Presentation

Clinical Utility of Molecular Markers Presentation


Professor de Bono presents the clinical utility of predictive molecular biomarkers in advanced prostate cancer during the first session of the Advanced Prostate Cancer Consensus Conference (APCCC 2019).  


Johann de Bono, MB ChB FRCP MSc Ph.D. FMedSci.  Professor Johann de Bono is Regius Professor of Cancer Research and a Professor in Experimental Cancer Medicine at The Institute of Cancer Research and The Royal Marsden NHS Foundation Trust.

He is also the Director of the Drug Development Unit, overseeing the conduct of phase I trials, with a particular interest in innovative trial designs, circulating biomarkers and prostate cancer. Additionally, he leads the Prostate Cancer Targeted Therapy Group and the Cancer Biomarkers laboratory team.

This site uses Akismet to reduce spam. Learn how your comment data is processed.